Critical Contrast: BeOne Medicines (NASDAQ:ONC) versus Korro Bio (NASDAQ:KRRO)

Korro Bio (NASDAQ:KRRO) and BeOne Medicines (NASDAQ:ONC) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, profitability, risk and dividends.

Earnings and Valuation

This table compares Korro Bio and BeOne Medicines”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39 million	28.65	-$117.26 million	($11.67)	-1.09
BeOne Medicines	$5.34 billion	7.11	$286.93 million	$4.47	77.48

BeOne Medicines has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

13.2% of Korro Bio shares are owned by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are owned by institutional investors. 4.8% of Korro Bio shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Korro Bio has a beta of 3.04, meaning that its share price is 204% more volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Korro Bio and BeOne Medicines, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1	2	6	3	2.92
BeOne Medicines	1	2	12	2	2.88

Korro Bio currently has a consensus target price of $16.71, indicating a potential upside of 31.66%. BeOne Medicines has a consensus target price of $400.00, indicating a potential upside of 15.50%. Given Korro Bio’s stronger consensus rating and higher possible upside, equities analysts plainly believe Korro Bio is more favorable than BeOne Medicines.

Profitability

This table compares Korro Bio and BeOne Medicines’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-117.86%	-71.04%
BeOne Medicines	10.70%	14.85%	8.07%

Summary

BeOne Medicines beats Korro Bio on 10 of the 15 factors compared between the two stocks.

About Korro Bio

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.